Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BCYC logo BCYC
Upturn stock ratingUpturn stock rating
BCYC logo

Bicycle Therapeutics Ltd (BCYC)

Upturn stock ratingUpturn stock rating
$7.08
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: BCYC (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

13 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $23.91

1 Year Target Price $23.91

Analysts Price Target For last 52 week
$23.91 Target price
52w Low $6.1
Current$7.08
52w High $28.67

Analysis of Past Performance

Type Stock
Historic Profit -29.35%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 490.69M USD
Price to earnings Ratio -
1Y Target Price 23.91
Price to earnings Ratio -
1Y Target Price 23.91
Volume (30-day avg) 13
Beta 1.45
52 Weeks Range 6.10 - 28.67
Updated Date 08/28/2025
52 Weeks Range 6.10 - 28.67
Updated Date 08/28/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.52

Earnings Date

Report Date 2025-08-08
When -
Estimate -0.94
Actual -1.14

Profitability

Profit Margin -
Operating Margin (TTM) -2965.82%

Management Effectiveness

Return on Assets (TTM) -19.07%
Return on Equity (TTM) -31.42%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -229108423
Price to Sales(TTM) 25.45
Enterprise Value -229108423
Price to Sales(TTM) 25.45
Enterprise Value to Revenue 21.22
Enterprise Value to EBITDA -2.14
Shares Outstanding 49868600
Shares Floating 1884365
Shares Outstanding 49868600
Shares Floating 1884365
Percent Insiders 1.4
Percent Institutions 88.49

ai summary icon Upturn AI SWOT

Bicycle Therapeutics Ltd

stock logo

Company Overview

overview logo History and Background

Bicycle Therapeutics Ltd was founded in 2009, based on the work of Sir Gregory Winter, a Nobel Laureate. The company focuses on developing a novel class of therapeutics based on bicyclic peptides (Bicyclesu2122). Significant milestones include advancing multiple Bicycle-based therapeutics into clinical trials and establishing partnerships with major pharmaceutical companies.

business area logo Core Business Areas

  • Oncology: Development of Bicycle Toxin Conjugates (BTCs) and Bicycle Tumor-Targeting Immunomodulators (BTTIs) for solid tumors.
  • Other Therapeutics: Exploration of Bicycle technology for other therapeutic areas beyond oncology, including immune-mediated diseases.

leadership logo Leadership and Structure

The leadership team consists of experienced executives in drug development and commercialization. The organizational structure is typical of a biotech company, with research, development, clinical, and commercial functions.

Top Products and Market Share

overview logo Key Offerings

  • BT8009 (NCT04992758): A Bicycle Toxin Conjugate (BTC) targeting Nectin-4, currently in Phase I/II trials for solid tumors. Market share is not applicable as it's still in development. Competitors targeting Nectin-4 include Astellas and Seagen (PADCEV).
  • BT5500 (NCT04579655): A Bicycle Toxin Conjugate (BTC) targeting EphA2, also in Phase I/II trials for solid tumors. Market share is not applicable as it's still in development. Competitors targeting EphA2 include various antibody-drug conjugates.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is highly competitive, with significant investments in research and development for new therapeutics. Oncology is a major area of focus with high unmet medical needs.

Positioning

Bicycle Therapeutics is positioned as a company developing a novel therapeutic modality with potential advantages in terms of tumor penetration, target specificity, and safety compared to traditional antibodies.

Total Addressable Market (TAM)

The total addressable market for oncology therapeutics is estimated to be in the hundreds of billions of dollars. Bicycle Therapeutics aims to capture a portion of this market with its Bicycle-based therapies.

Upturn SWOT Analysis

Strengths

  • Novel Bicycle technology platform
  • Strong intellectual property position
  • Experienced leadership team
  • Partnerships with major pharmaceutical companies

Weaknesses

  • Early-stage clinical development
  • Reliance on external funding
  • Uncertainty regarding clinical trial outcomes
  • Limited commercial infrastructure

Opportunities

  • Expansion of Bicycle technology into new therapeutic areas
  • Out-licensing or partnering of Bicycle-based therapeutics
  • Advancement of clinical programs to late-stage development
  • Potential for breakthrough therapy designation

Threats

  • Clinical trial failures
  • Competition from other therapeutic modalities
  • Regulatory hurdles
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • LLY
  • MRK
  • BMY
  • AZN

Competitive Landscape

Bicycle Therapeutics competes with large pharmaceutical companies developing cancer therapies and smaller biotech firms with novel therapeutic modalities. BCYC's advantages lie in its unique Bicycle technology and targeted approach. Disadvantages include its early stage development and limited resources compared to larger competitors.

Growth Trajectory and Initiatives

Historical Growth: Growth is driven by clinical trial progress, partnership agreements, and financing activities.

Future Projections: Future projections are based on analyst estimates and company guidance. These can change.

Recent Initiatives: Recent initiatives include advancing clinical programs, expanding partnerships, and securing financing.

Summary

Bicycle Therapeutics is a biotech company with a promising novel technology platform. Its strength lies in its unique Bicycle-based therapeutics, but its weaknesses are related to its early stage of development and financial reliance. Potential threats include clinical trial failures and competition from larger pharma companies. The company has the potential to grow significantly through partnerships and clinical success.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Bicycle Therapeutics Ltd.'s SEC Filings
  • Bicycle Therapeutics Ltd.'s Investor Relations
  • Analyst Reports
  • Industry Publications

Disclaimers:

The data and analysis provided are for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Financial data is subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Bicycle Therapeutics Ltd

Exchange NASDAQ
Headquaters -
IPO Launch date 2019-05-23
CEO & Executive Director Dr. Kevin Lee M.B.A., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 305
Full time employees 305

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; and BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that is in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; and Genentech, Inc. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.